Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.
Context Therapeutics, a US-based developer of treatments for cancers affecting women based on research at Drexel University, has filed for an initial public offering that could raise up to $21m.
The company will issue 1.5 million shares and has set a price range of $12 to $14. It aims to list on Nasdaq Capital Market using the ticker symbol CNTX.
Founded in 2015, Context Therapeutics is working on advanced small molecule and immunotherapy treatments for hormone-driven breast…
